Elevated IL-35 in bone marrow of the patients with acute myeloid leukemia

Human Immunology

Volumn 76, Issue 9, 2015, Pages 681-686

  Wang, Jia ^a   Tao, Qianshan ^a   Wang, Huiping ^a   Wang, Zhitao ^a   Wu, Fan ^a   Pan, Ying ^a   Tao, Lili ^a   Xiong, Shudao ^a   Wang, Yiping ^b   Zhai, Zhimin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Acute myeloid leukemia; Bone marrow; IL 35; Immune escape

Indexed keywords

INTERLEUKIN 35; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; MESSENGER RNA;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER PATIENT; CLINICAL ARTICLE; COMPLETE REMISSION; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; CANCER STAGING; CHROMOSOME ABERRATION; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE MARROW; CHROMOSOME ABERRATIONS; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER; YOUNG ADULT;

EID: 84944381957     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2015.09.020     Document Type: Article

References (26)

1. Estey E.H. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am. J. Hematol. 2013, 88(4):318-327.
2. Szczepanski M.J., Szajnik M., Czystowska M., Mandapathil M., Strauss L., Welsh A., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin. Cancer Res. 2009, 15(10):3325-3332.
3. Ustun C., Miller J.S., Munn D.H., Weisdorf D.J., Blazar B.R. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. Blood 2011, 118(19):5084-5095.
4. Yang W., Xu Y. Clinical significance of Treg cell frequency in acute myeloid leukemia. Int. J. Hematol. 2013, 98(5):558-562.
5. Wu H., Li P., Shao N., Ma J., Ji M., Sun X., et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncol. Lett. 2012, 3(5):1119-1123.
6. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450(7169):566-569.
7. Niedbala W., Wei X.Q., Cai B., Hueber A.J., Leung B.P., McInnes I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 2007, 37(11):3021-3029.
8. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J. Immunol. 2009, 182(10):6121-6128.
9. Tao Q., Pan Y., Wang Y., Wang H., Xiong S., Li Q., et al. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts. Int. J. Cancer 2015, 10.1002/ijc.29563.
10. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 2003, 21:4642.
11. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133(5):775-787.
12. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11(12):1093-1101.
13. Huang C.H., Loo E.X., Kuo I.C., Soh G.H., Goh D.L., Lee B.W., et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J. Immunol. 2011, 187(1):462-471.
14. Wirtz S., Billmeier U., McHedlidze T., Blumberg R.S., Neurath M.F. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011, 141(5):1875-1886.
15. Kochetkova I., Golden S., Holderness K., Callis G., Pascual D.W. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J. Immunol. 2010, 184(12):7144-7153.
16. + regulatory T cells do not constitutively express IL-35. J. Immunol. 2008, 181(10):6898-6905.
17. Zeng J.C., Zhang Z., Li T.Y., Liang Y.F., Wang H.M., Bao J.J., et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int. J. Clin. Exp. Pathol. 2013, 6(9):1806-1816.
18. Jin P., Ren H., Sun W., Xin W., Zhang H., Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum. Immunol. 2014, 75(1):29-33.
19. Liu Y., Wu Y., Wang Y., Cai Y., Hu B., Bao G., et al. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia 2015, 29(4):939-946.
20. Zhang X., Zhou Y., Xu L., Han W., Chen H., Chen Y., et al. Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 2015, 94(5):837-845.
21. Stone R.M., O'Donnell M.R., Sekeres M.A. Acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program. 2004, 98-117.
22. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(7):2292-2302.
23. Sun Y.X., Kong H.L., Liu C.F., Yu S., Tian T., Ma D.X., et al. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum. Immunol. 2014, 75(2):113-118.
24. Guttek K., Reinhold D. Stimulated human peripheral T cells produce high amounts of IL-35 protein in a proliferation-dependent manner. Cytokine 2013, 64(1):46-50.
25. Ferretti E., Di Carlo E., Cocco C., Ribatti D., Sorrentino C., Ognio E., et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol. Lett. 2010, 133(2):99-105.
26. Zorzoli A., Di Carlo E., Cocco C., Ognio E., Ribatti D., Ferretti E., et al. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin. Cancer Res. 2012, 18(6):1630-1640.